Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional Analgesia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Needham & Company Downgrades Pacira Pharmaceuticals (PCRX) to Hold
February 16, 2018 7:20 AM ESTNeedham & Company downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold.
Analyst Serge Belanger commented, "The FDA's briefing documents presaged a difficult AdCom panel review for Exparel's potential label expansion to nerve blocks. Over the 2-day panel, panel members echoed the FDA's concerns... More
Pacira Pharmaceuticals (PCRX) PT Lowered to $32 at BMO Capital
February 16, 2018 6:11 AM ESTBMO Capital lowered its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $32.00 (from $41.00) while maintaining a Market Perform rating.
Analyst Gary Nachman commented, "FDA panel voted against approving the nerve block (NB) indication for Exparel (6 No, 4 Yes). We anticipated a complicated... More
Pacira Pharma (PCRX) to Resume Trading at 4:15 pm ET
February 15, 2018 3:51 PM ESTPacira Pharma (NASDAQ: PCRX) to Resume Trading at 4:15 pm ET
... MorePacira Pharma (PCRX) Confirms Only Four FDA Committee Members Voted to Recommend Approval of EXPAREL sNDA
February 15, 2018 3:36 PM ESTPacira Pharmaceuticals, Inc. (NASDAQ: PCRX), announced today that the U.S. Food and Drug Administrations (FDA) Anesthetic and Analgesic Drug Products Advisory Committee did not reach a unanimous decision on the efficacy and safety of the use of EXPAREL® (bupivacaine liposome injectable suspension) as a nerve block to produce regional analgesia. The committees feedback will be considered by the FDA in its review of the companys sNDA seeking expansion of the... More
